Biotech Values

[DewDiligence]

GTCB webcast: Cox was on his game!

I just heard GTCB’s Rodman & Renshaw webcast live from Paris, France and I am pleased to report that Dr. Cox was the most lucid and confident he has ever been – by far!

Here is a new piece of information that I consider telling: the EMEA has made plans to inspect GTC’s Pharm in Massachusetts. Would the EMEA travel all the way to Massachusetts to see GTC’s facilities if they were not planning to approve ATryn? I don’t think so.

Listen to the webcast replay and decide for yourself:

http://www.rodmanandrenshaw.com/rodman.asp?link=Conferences5/ConferenceWebcasters&bgcolor=wht

I may be sleep-deprived but I am not crazy. The company’s fully-diluted valuation net of cash on hand is only about $30M. If you don’t agree that GTCB at this price is one of the greatest biotech opportunities you will ever see, I would like to know why!